Axicabtagene Ciloleucel (Yescarta®): A Comprehensive Clinical and Scientific Review

I. Executive Summary

Axicabtagene ciloleucel, marketed under the brand name Yescarta®, is a CD19-directed, genetically modified autologous T-cell immunotherapy that represents a paradigm shift in the treatment of certain B-cell malignancies.[1] As a living drug, it is manufactured on a patient-specific basis by harvesting a patient's T-cells, engineering them

ex vivo to express a chimeric antigen receptor (CAR) that targets the CD19 protein on lymphoma cells, and infusing them back into the patient to elicit a potent anti-tumor immune response.[2] This report provides a comprehensive analysis of its foundational science, clinical evidence, regulatory history, and therapeutic context.

The clinical development of axicabtagene ciloleucel has been marked by landmark trials demonstrating profound and durable efficacy. The pivotal ZUMA-1 trial established its value in the third-line or later setting for relapsed or refractory (R/R) large B-cell lymphoma (LBCL), showing a 5-year overall survival rate of 42.6% in a patient population with a historically dismal prognosis, suggesting curative potential for a significant subset of patients.[4] More significantly, the randomized Phase 3 ZUMA-7 trial demonstrated the superiority of axicabtagene ciloleucel over the long-standing standard of care (SOC)—salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant—in the second-line treatment of high-risk LBCL.[1] This trial led to a fundamental reordering of the treatment algorithm, establishing CAR-T therapy as a new standard in an earlier line of treatment for patients with primary refractory disease or early relapse.[7]

This transformative efficacy is, however, balanced by a significant and unique toxicity profile. Axicabtagene ciloleucel carries a U.S. Food and Drug Administration (FDA) Black Box Warning for two potentially life-threatening adverse events: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[9] The high incidence of these toxicities necessitates administration in certified healthcare facilities by specially trained teams and is managed through a mandatory Risk Evaluation and Mitigation Strategy (REMS) program.[12]

With a high acquisition cost, axicabtagene ciloleucel also presents considerable economic challenges to healthcare systems, though analyses suggest it is cost-effective due to its potential for durable, long-term remission.[14] In a competitive landscape with other approved CAR-T therapies, its distinct clinical profile—characterized by rapid, potent efficacy and acute toxicity—positions it as a critical but carefully selected option. Ongoing research and continuous manufacturing process improvements are focused on enhancing its safety profile, reducing vein-to-vein time, and exploring its use in even earlier lines of therapy and in combination with other novel agents, further solidifying the role of axicabtagene ciloleucel as a cornerstone of modern hematologic oncology.[17]

II. Foundational Science: Engineering a Living Drug

The development of axicabtagene ciloleucel is rooted in decades of advances in immunology and genetic engineering. It embodies the concept of a "living drug," where a patient's own immune cells are reprogrammed to become highly specific and potent cancer-killing agents. Understanding its molecular design and the intricate manufacturing process is fundamental to appreciating both its therapeutic power and its clinical challenges.

2.1. Mechanism of Action: Targeting CD19

The therapeutic activity of axicabtagene ciloleucel is driven by its engineered ability to recognize and eliminate cancer cells through a mechanism that bypasses the conventional requirements of T-cell activation.

The Target

Axicabtagene ciloleucel is designed to target the B-lymphocyte antigen CD19.[2] CD19 is a transmembrane glycoprotein that is a hallmark of the B-cell lineage, expressed from early pro-B-cell stages through to mature B-cells, but absent on hematopoietic stem cells and plasma cells. Crucially, it is expressed on the surface of malignant cells in the vast majority of B-cell neoplasms, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).[2] This consistent and widespread expression on cancer cells, coupled with its absence on most other tissues, makes CD19 an excellent target for immunotherapy, allowing for specific targeting of the malignancy.[2]

The CAR Construct

The core of the therapy is the chimeric antigen receptor (CAR), a synthetic, multi-domain protein engineered to be expressed on the surface of T-cells. The specific CAR construct in axicabtagene ciloleucel is a second-generation design composed of three key functional parts [20]:

1. Antigen-Recognition Domain: The extracellular portion of the CAR is a murine anti-CD19 single-chain variable fragment (scFv). This component is derived from an antibody and serves as the "warhead," providing high-affinity binding specifically to the CD19 protein on target cells.[21]
2. Co-stimulatory Domain: Linked to the scFv is the intracellular CD28 co-stimulatory domain.[22] In natural T-cell activation, co-stimulation is a critical "second signal" required for a robust and sustained immune response. The inclusion of the CD28 domain in the CAR construct provides this powerful activating signal directly upon antigen binding.
3. Signaling Domain: The primary intracellular signaling component is the CD3-zeta (CD3ζ) chain, which is part of the natural T-cell receptor complex. This domain provides the "first signal" for T-cell activation.[21]

The choice of the CD28 co-stimulatory domain is a defining feature of axicabtagene ciloleucel and a key differentiator from other CAR-T therapies, such as tisagenlecleucel, which utilizes a 4-1BB domain.[26] This design choice has profound clinical implications. The CD28 signal is known to promote rapid and powerful T-cell activation, explosive proliferation, and high levels of cytokine production.[24] This aggressive signaling cascade is believed to be the primary driver of both the remarkable efficacy seen with axicabtagene ciloleucel, characterized by high and rapid response rates, and its signature acute toxicity profile, marked by high rates of severe CRS and ICANS. In contrast, the 4-1BB domain provides a more delayed and sustained signal, which may lead to enhanced T-cell persistence but generally results in a less intense initial activation, correlating with a more favorable acute toxicity profile but potentially different efficacy kinetics.[26] This makes the CD28 domain a "double-edged sword," endowing the therapy with its potent anti-tumor activity at the cost of significant, predictable toxicities that require specialized management.

Cellular Activation and Cytotoxicity

When an axicabtagene ciloleucel CAR T-cell encounters a CD19-expressing cancer cell, the scFv binds to the CD19 antigen. This binding event clusters the CARs on the T-cell surface, triggering the intracellular CD28 and CD3ζ domains to initiate a potent downstream signaling cascade.[2] This activation is independent of the major histocompatibility complex (MHC), a system that cancer cells often downregulate to evade detection by the natural immune system.[25]

The signaling cascade leads to a series of events that culminate in the destruction of the target cell:

• T-Cell Activation and Proliferation: The engineered T-cells become fully activated and begin to proliferate rapidly, creating an army of cancer-fighting cells in vivo.[24]
• Secretion of Inflammatory Cytokines: Activated CAR T-cells release a flood of inflammatory cytokines, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), and chemokines. These molecules recruit other immune cells to the tumor site, amplifying the anti-tumor response, but are also the primary mediators of CRS.[2]
• Direct Cytotoxicity: The CAR T-cells directly kill the cancer cells by releasing cytotoxic granules containing perforin and granzymes, which induce apoptosis (programmed cell death) in the CD19-positive target cells.[3]

The ability of these engineered cells to persist and remain active in the body for weeks to months contributes to the durable remissions observed in clinical trials.[25]

2.2. The Vein-to-Vein Journey: Manufacturing and Logistics

Axicabtagene ciloleucel is an autologous therapy, meaning it is created uniquely for each patient from their own cells. The complex, multi-step process from cell collection to infusion is often referred to as the "vein-to-vein" journey and is a critical determinant of the therapy's success.[28]

1. Step 1: Leukapheresis: The process begins at a qualified treatment center where the patient undergoes leukapheresis. This is a non-surgical procedure, typically lasting 3 to 4 hours, in which blood is drawn from the patient, passed through a machine that separates out the white blood cells (leukocytes), and the remaining blood components are returned to the patient's circulation. The collected material, rich in T-cells, is the starting material for manufacturing.[3]
2. Step 2: T-Cell Isolation and Activation: The leukapheresis product is shipped to a centralized, state-of-the-art Kite Pharma manufacturing facility.[28] There, T-lymphocytes are isolated from the other peripheral blood mononuclear cells (PBMCs). The cells are then activated ex vivo, a process that prepares them for genetic modification. This is often accomplished using magnetic beads coated with anti-CD3 and anti-CD28 antibodies, which mimic the natural signals for T-cell activation.[29]
3. Step 3: Genetic Modification (Transduction): In the most critical step, the activated T-cells are transduced with a replication-incompetent retroviral vector.[21] This vector acts as a delivery vehicle, carrying the gene that encodes the anti-CD19 CAR. The vector introduces this genetic material into the T-cells, where it integrates into the cells' genome. This permanent integration ensures that the CAR protein will be stably expressed on the cell surface and passed down to all daughter cells during subsequent proliferation.[22]
4. Step 4: Expansion: The newly engineered CAR T-cells are cultured in specialized bioreactors for several days. They are provided with essential nutrients and growth factors (such as IL-2) to encourage them to multiply into the hundreds of millions or billions of cells required for a therapeutic dose.[2]
5. Step 5: Formulation and Cryopreservation: Once the target cell number is reached, the CAR T-cell product is harvested. The cells are washed to remove residual materials from the manufacturing process, concentrated, and formulated into a final suspension for infusion. This final product is then cryopreserved (frozen) in a patient-specific infusion bag to maintain its viability and potency during shipment.[29]
6. Step 6: Lymphodepletion and Infusion: The cryopreserved product is shipped back to the certified treatment center. In the days leading up to the infusion (typically starting 5 days prior), the patient receives a lymphodepleting chemotherapy regimen, consisting of low-dose fludarabine and cyclophosphamide.[1] This chemotherapy temporarily reduces the number of the patient's existing lymphocytes, which serves two key purposes: it reduces competition for resources and creates a more favorable cytokine environment for the incoming CAR T-cells to engraft, expand, and persist. Finally, the axicabtagene ciloleucel product is thawed at the patient's bedside and administered as a single intravenous infusion.[21]

The entire vein-to-vein process is a logistical and scientific feat where time is of the essence. The efficiency and reliability of this process are not merely operational metrics; they are critical clinical variables and a key competitive differentiator. The median turnaround time (TAT) for axicabtagene ciloleucel is remarkably consistent, reported at approximately 14 days in the US and 17 days globally.[13] This is significantly shorter than the TAT reported for some competing CAR-T therapies, such as lisocabtagene maraleucel (median of 41 days in one study).[35] This difference is clinically meaningful. For patients with aggressive, rapidly progressing lymphoma, a shorter TAT reduces the duration and potential need for bridging therapy (treatment given to control the cancer while waiting for the CAR-T cells), minimizes the risk of the patient's condition deteriorating to the point of being ineligible for infusion, and can be a decisive factor for clinicians when choosing between products.[35] Kite/Gilead's continuous process improvements have led to a first-pass manufacturing success rate of over 94% and a delivery success rate of over 99% in 2023, ensuring that this life-saving therapy can be reliably delivered to patients in a timely manner.[18] This demonstrates that excellence in bioprocess engineering and logistics directly translates into improved patient access and is a crucial component of the therapy's overall value proposition.

2.3. Clinical Pharmacology

As a living drug, axicabtagene ciloleucel has a unique pharmacological profile that is described in terms of its cellular kinetics (pharmacokinetics) and its biological effects on the body (pharmacodynamics).

Pharmacokinetics (Cellular Kinetics)

The pharmacokinetics of axicabtagene ciloleucel describe the expansion, distribution, and persistence of the CAR T-cells in the patient's body following infusion.

• Expansion: After a single intravenous infusion, the CAR T-cells undergo rapid and massive proliferation in vivo. Peak levels of anti-CD19 CAR T-cells in the blood (Cmax) are typically observed within the first 7 to 14 days.[2] The median peak level ( Cmax​) in one analysis was 38.3 cells/µL.[2]
• Correlation with Response: The magnitude of this initial expansion is a key determinant of clinical outcome. Studies have consistently shown a strong positive correlation between higher peak CAR T-cell levels and a greater area under the curve (AUC) of cell concentration over the first 28 days and the likelihood of achieving an objective clinical response.[5] In the ZUMA-1 trial, the median CAR T-cell AUC was 5.4 times higher in patients who responded to therapy compared to those who did not. This expansion is also associated with the severity of neurologic events but, interestingly, not with the severity of CRS.[39]
• Persistence: Following the peak, the number of CAR T-cells in circulation gradually declines. By three months post-infusion, levels are typically near baseline, although they often remain detectable at low levels for many months or even years in some patients.[2] The clinical significance of long-term persistence for maintaining durable remission in LBCL is an area of active investigation. Notably, long-term complete remissions have been documented even with limited CAR T-cell persistence and the recovery of normal B-cells, suggesting that protracted B-cell aplasia (a marker of CAR T-cell activity) is not an absolute requirement for a cure.[4]

Pharmacodynamics

The pharmacodynamic effects of axicabtagene ciloleucel encompass the biological responses elicited by the drug, including cytokine release and on-target, off-tumor effects.

• Cytokine Elevation: The primary pharmacodynamic effect is the massive, transient release of inflammatory cytokines and chemokines by the activated CAR T-cells and other responding immune cells. Levels of key cytokines, including interleukin-6 (IL-6), IL-8, IL-10, IL-15, IFN-γ, and TNF-α, peak within the first 14 days after infusion.[2] This cytokine storm directly correlates with the timing of peak CAR T-cell expansion and is the underlying cause of the clinical syndrome of CRS. These cytokine levels generally return to baseline within 28 days.[2]
• On-Target, Off-Tumor Effects: Because the CAR T-cells target the CD19 antigen, they cannot distinguish between malignant B-cells and healthy B-cells. This leads to an expected "on-target, off-tumor" effect: the elimination of the patient's normal B-cell population. This results in B-cell aplasia, which can be prolonged, and a consequent state of hypogammaglobulinemia (low levels of antibodies).[2] This effect increases the patient's susceptibility to infections and may require long-term management with intravenous immunoglobulin (IVIG) replacement therapy.[41]

Characteristic	Description
Generic Name	Axicabtagene ciloleucel
Brand Name	Yescarta®
Alternative Names	KTE-C19, Axi-cel
DrugBank ID	DB13915
Type	Biotech, Genetically Modified Autologous T-cell Immunotherapy
Developer/Company	Kite Pharma, a Gilead Company 1
Target Antigen	CD19 2
CAR Construct	Murine anti-CD19 scFv, CD28 co-stimulatory domain, CD3-zeta signaling domain 21
Vector	Retroviral vector 22
Administration Route	Intravenous infusion 1

III. Clinical Development and Regulatory Landscape

The journey of axicabtagene ciloleucel from an experimental therapy to a standard of care has been rapid and transformative, marked by a series of strategic clinical trials and landmark regulatory approvals that have reshaped the treatment of B-cell lymphomas.

3.1. Approved Indications

Axicabtagene ciloleucel has secured approvals from major regulatory bodies for several indications in adult patients, with some differences between regions.

United States (FDA)

In the United States, Yescarta is indicated for the treatment of:

• Large B-Cell Lymphoma (LBCL):
• Second-Line Treatment: Adult patients with LBCL that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.[1] This indication positions it as a new standard of care for a high-risk population.
• Third-Line or Later Treatment: Adult patients with relapsed or refractory (R/R) LBCL after two or more lines of systemic therapy. This includes several subtypes: diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL), and DLBCL arising from follicular lymphoma.[12]
• Follicular Lymphoma (FL):
• Third-Line or Later Treatment: Adult patients with R/R FL after two or more lines of systemic therapy. This indication was granted under the FDA's accelerated approval program based on response rate, with continued approval contingent on confirmatory trials.[22]

A key Limitation of Use specified by the FDA is that Yescarta is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.[1]

European Union (EMA)

In the European Union, the indications for Yescarta are largely similar, with minor differences:

• Large B-Cell Lymphoma (LBCL):
• Second-Line Treatment: Adult patients with DLBCL and HGBL that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.[23]
• Third-Line or Later Treatment: Adult patients with R/R DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.[21]
• Follicular Lymphoma (FL):
• Fourth-Line or Later Treatment: Adult patients with R/R FL after three or more lines of systemic therapy, a slightly later line of treatment compared to the US indication.[21]

3.2. Global Regulatory Approvals: A Timeline of Milestones

The regulatory pathway for axicabtagene ciloleucel was expedited by its clear potential to address a major unmet medical need, earning it special designations such as Breakthrough Therapy, Priority Review, and Orphan Drug status from the FDA, and Orphan Designation and Priority Medicines (PRIME) scheme inclusion from the EMA.[1]

This regulatory journey tells a compelling story of a therapy's evolution. Initially approved as a salvage option for patients who had exhausted all other possibilities, its profound efficacy paved the way for it to challenge and ultimately replace the established standard of care in an earlier treatment setting. This progression from a "last resort" to a "new standard" is a critical inflection point in the history of cancer therapy. It reflects not only the drug's powerful clinical benefit but also the growing confidence and expertise within the medical and regulatory communities in managing its unique and significant toxicities. This validation of the therapeutic concept has had far-reaching implications for clinical practice guidelines, patient eligibility criteria, and the allocation of healthcare resources.

• November 11, 2015: The European Commission grants orphan designation for the treatment of follicular lymphoma, recognizing its potential benefit for a rare disease.[48]
• October 18, 2017: The U.S. FDA grants regular approval to Yescarta for adult patients with R/R LBCL after two or more lines of systemic therapy. This landmark decision was based on the pivotal ZUMA-1 trial and made axicabtagene ciloleucel the first CAR T-cell therapy approved for this indication, offering a new therapeutic modality for patients with otherwise dismal prognoses.[1]
• August 23, 2018: The European Commission grants Marketing Authorization for Yescarta in the EU for adult patients with R/R DLBCL and PMBCL after two or more lines of systemic therapy, bringing the therapy to patients in Europe.[22]
• March 5, 2021: The FDA grants accelerated approval for the treatment of adult patients with R/R FL after two or more lines of systemic therapy. This approval, based on the ZUMA-5 trial, expanded the use of axicabtagene ciloleucel to another common type of non-Hodgkin lymphoma.[46]
• April 1, 2022: In what represents a major paradigm shift, the FDA grants regular approval for Yescarta as a second-line treatment for adults with LBCL that is refractory to first-line therapy or relapses within 12 months. This approval was based on the head-to-head ZUMA-7 trial, which demonstrated the superiority of axicabtagene ciloleucel over the existing standard of care. It was the first time a CAR-T therapy was approved in the second-line setting for LBCL, fundamentally changing the treatment landscape.[1]
• June 21, 2022: Following its earlier orphan designation, the medicinal product is formally authorized in the EU as Yescarta for follicular lymphoma.[48]

IV. The Evidence Base: Analysis of Pivotal Clinical Trials

The clinical value of axicabtagene ciloleucel is built upon a foundation of robust evidence from a series of well-designed clinical trials. The ZUMA program, in particular, has systematically demonstrated the therapy's efficacy and safety, leading to its regulatory approvals and adoption into clinical practice.

4.1. ZUMA-1 (NCT02348216): Establishing a New Hope in Third-Line Therapy

The ZUMA-1 trial was the pivotal study that first established the transformative potential of axicabtagene ciloleucel in a population with a dire need for new treatment options.

Design and Population

ZUMA-1 was a single-arm, multicenter Phase 1/2 trial that enrolled 111 adult patients, with 101 ultimately receiving the axicabtagene ciloleucel infusion.[49] The participants had refractory aggressive B-cell non-Hodgkin lymphoma, including DLBCL, PMBCL, or transformed follicular lymphoma (TFL). These were heavily pretreated patients who were refractory to their most recent chemotherapy regimen or had relapsed within 12 months of an autologous stem cell transplant (ASCT)—a group with a median overall survival historically measured in months.[12] Patients received a single infusion of axicabtagene ciloleucel at a target dose of

2×106 CAR-positive viable T-cells/kg following a standard lymphodepleting regimen of fludarabine and cyclophosphamide.[4]

Efficacy Outcomes

The results from ZUMA-1 were unprecedented for this patient population and led to the initial FDA approval.

• Response Rates: The trial reported an exceptionally high objective response rate (ORR) of 82% to 83%, as assessed by both local investigators and an independent review committee. Even more remarkably, the complete response (CR) rate—the disappearance of all signs of cancer—was 54% to 58%.[5] A key finding was that responses could deepen over time; analysis showed that 32% of patients who had a partial response (PR) at one month converted to a CR with longer follow-up, some as late as a year after infusion.[51]
• Durability and Survival: The long-term follow-up from ZUMA-1 demonstrated that these responses were not fleeting. With a median follow-up of 63.1 months (over 5 years), 31% of patients had an ongoing response, with 30% remaining in a complete response.[4] The median overall survival (OS) for the entire cohort was 25.8 months, and the estimated 5-year OS rate was 42.6%.[4] For the patients who achieved a CR, the outcomes were even more striking: the median OS was not reached, and the 5-year OS rate was 64.4%.[4] The emergence of a plateau on the survival curve after several years of follow-up strongly suggests that a substantial fraction of these patients with previously incurable disease may have been cured by a single infusion of axicabtagene ciloleucel.

4.2. ZUMA-7 (NCT03391466): A Paradigm Shift in Second-Line Treatment

While ZUMA-1 proved axicabtagene ciloleucel's value as a salvage therapy, the ZUMA-7 trial was designed to ask a more ambitious question: could this therapy be superior to the established standard of care in an earlier line of treatment?

Design and Population

ZUMA-7 was a global, randomized, open-label, multicenter Phase 3 trial—the gold standard for clinical evidence. It enrolled 359 patients with early relapsed or refractory LBCL, defined as those whose disease was refractory to first-line chemoimmunotherapy or who relapsed within 12 months of completing it.[1] Patients were randomized in a 1:1 ratio to receive either a single infusion of axicabtagene ciloleucel (n=180) or the traditional standard of care (SOC) (n=179). The SOC arm consisted of two to three cycles of a platinum-based salvage chemoimmunotherapy regimen, with those who responded proceeding to high-dose chemotherapy and ASCT.[1]

Primary Endpoint (Event-Free Survival)

The trial met its primary endpoint with resounding success, demonstrating a clear and statistically significant superiority for axicabtagene ciloleucel.

• At a median follow-up of 24.9 months, the median event-free survival (EFS)—the time patients lived without their cancer progressing, needing new treatment, or death—was 8.3 months in the axicabtagene ciloleucel arm. This was more than four times longer than the median EFS of just 2.0 months in the SOC arm.[8]
• The hazard ratio (HR) for an event or death was 0.40, indicating a 60% reduction in the risk of an event for patients receiving axicabtagene ciloleucel.[8]
• The 24-month EFS rate was 41% for the axicabtagene ciloleucel group, compared to only 16% for the SOC group.[8]

Key Secondary Endpoint (Overall Survival)

The primary overall survival analysis, conducted at a median follow-up of 47.2 months, confirmed that the EFS benefit translated into patients living longer.

• Median OS was not reached in the axicabtagene ciloleucel group, versus 31.1 months in the SOC group (HR 0.73), a statistically significant improvement.[6]
• The estimated 4-year OS rate was 54.6% for axicabtagene ciloleucel versus 46.0% for SOC.[1]
• This survival benefit was achieved despite the fact that 57% of patients in the SOC arm who progressed went on to receive cellular immunotherapy (most commonly, commercially available axicabtagene ciloleucel) as a subsequent therapy.[6] This high rate of crossover treatment likely diluted the observed OS difference, meaning the true survival benefit of using axicabtagene ciloleucel in the second-line setting is probably even greater than what was reported.

Patient-Reported Outcomes (PROs)

ZUMA-7 also included a prospective evaluation of quality of life (QoL), a critical measure of the patient experience. Despite the acute toxicities associated with CAR-T therapy, patients in the axicabtagene ciloleucel arm reported statistically significant and clinically meaningful improvements in their global health status and physical functioning compared to those undergoing months of salvage chemotherapy in the SOC arm, particularly at the day 100 and day 150 time points. This suggests a faster recovery to baseline QoL with a one-time infusion of axicabtagene ciloleucel compared to the prolonged ordeal of conventional chemoimmunotherapy.[55]

The results of ZUMA-7 were not just an incremental advance; they were transformative. By demonstrating overwhelming superiority in EFS, a significant OS benefit, and a better QoL trajectory compared to the established multi-step SOC, the trial effectively rendered the old paradigm obsolete for this high-risk patient population. The combination of living longer and living better dismantled the rationale for subjecting these patients to salvage chemotherapy with a low probability of success, forcing a redefinition of clinical guidelines and cementing axicabtagene ciloleucel as the new standard of care for second-line R/R LBCL.

Trial	Indication / Line of Therapy	Comparator	N	Median Follow-up	ORR	CR Rate	Median EFS/PFS	Median OS	OS Rate (at follow-up)
ZUMA-1 4	3L+ R/R LBCL	Single-Arm	101	63.1 months	83%	58%	5.9 months (PFS)	25.8 months	42.6% (5-year)
ZUMA-7 (Axi-cel) 6	2L R/R LBCL	SOC	180	47.2 months	83%	65%	8.3 months (EFS)	Not Reached	54.6% (4-year)
ZUMA-7 (SOC) 6	2L R/R LBCL	Axi-cel	179	47.2 months	50%	32%	2.0 months (EFS)	31.1 months	46.0% (4-year)

V. Safety, Toxicity, and Risk Mitigation

The profound efficacy of axicabtagene ciloleucel is inextricably linked to its powerful mechanism of action, which also gives rise to a unique and significant toxicity profile. Effective management of these adverse events is paramount to the therapy's successful application and requires specialized expertise and infrastructure.

5.1. The Black Box Warning: CRS and ICANS

The U.S. FDA has mandated a Black Box Warning—the most serious type of warning in prescription drug labeling—for axicabtagene ciloleucel, highlighting the risk of two potentially fatal toxicities: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[9]

Cytokine Release Syndrome (CRS)

• Description and Pathophysiology: CRS is a systemic inflammatory response triggered by the massive and rapid release of cytokines from the activated CAR T-cells and other engaged immune cells, such as macrophages.[1] This "cytokine storm" can affect multiple organ systems, leading to a wide range of symptoms from mild, flu-like illness to life-threatening organ dysfunction.[9]
• Incidence and Onset: CRS is the most common toxicity, occurring in 88% to 94% of patients treated with axicabtagene ciloleucel for non-Hodgkin lymphoma.[9] While most cases are low-grade, severe (Grade ≥3) CRS occurs in approximately 9% to 13% of patients with LBCL.[5] The onset is typically rapid, with a median time of 2 to 4 days following infusion, and the median duration is about 7 days.[9]
• Management: Management of CRS is guided by consensus grading criteria from the American Society for Transplantation and Cellular Therapy (ASTCT). Grade 1 CRS (fever) is managed with supportive care. For Grade ≥2 CRS, which involves hypotension or hypoxia, the primary intervention is the administration of tocilizumab, an antibody that blocks the receptor for the key inflammatory cytokine IL-6.[10] This can lead to a rapid resolution of symptoms. For severe (Grade ≥3) or refractory CRS, corticosteroids such as dexamethasone or methylprednisolone are added to the regimen to broadly suppress the inflammatory response.[33]

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

• Description: ICANS is a distinct and complex neurological syndrome associated with CAR T-cell therapy. It can manifest with a wide spectrum of symptoms, including expressive aphasia (difficulty speaking), confusion, delirium, tremor, depressed level of consciousness, and, in severe cases, seizures or fatal cerebral edema.[1] The pathophysiology is not fully understood but is thought to involve inflammatory cytokines crossing the blood-brain barrier and direct effects of T-cells on the central nervous system. ICANS can occur concurrently with CRS or after CRS has resolved.[10]
• Incidence and Onset: ICANS is also very common, occurring in approximately 81% to 87% of LBCL patients receiving axicabtagene ciloleucel.[10] Severe (Grade ≥3) ICANS is a significant concern, affecting 21% to 31% of this population.[10] The median time to onset is typically around 4 to 5 days post-infusion.[10]
• Management: Like CRS, ICANS is graded using ASTCT criteria, which incorporate a simple 10-point cognitive assessment tool (the ICE score). The cornerstone of ICANS management is the prompt administration of corticosteroids, which are highly effective at crossing the blood-brain barrier and reducing neuroinflammation.[10] Tocilizumab is generally not effective for isolated ICANS but is used if severe CRS is also present.[33] In recent years, prophylactic use of corticosteroids has been explored and incorporated into practice to reduce the incidence and severity of ICANS.[9]

5.2. Other Clinically Significant Adverse Events

Beyond CRS and ICANS, patients receiving axicabtagene ciloleucel can experience several other important adverse events.

• Prolonged Cytopenias: Due to the lymphodepleting chemotherapy and the on-target effects of the therapy, patients frequently experience prolonged periods of low blood counts. Grade ≥3 neutropenia (low neutrophils), anemia (low red blood cells), and thrombocytopenia (low platelets) are very common and can increase the risk of infection and bleeding.[40]
• Hypogammaglobulinemia: The intended destruction of CD19-positive B-cells leads to B-cell aplasia and a subsequent inability to produce sufficient antibodies (immunoglobulins). This condition, known as hypogammaglobulinemia, occurred in 17% of patients in clinical trials and can persist for months to years, increasing the long-term risk of infections. It is often managed with regular infusions of intravenous immunoglobulin (IVIG).[40]
• Infections: Patients are at high risk for serious infections due to cytopenias and hypogammaglobulinemia. In trials, Grade ≥3 infections occurred in about 19% of patients. Prophylactic antimicrobial agents are often used, and patients are monitored closely for signs of infection.[40]
• Secondary Malignancies: As with other genetically modified cell therapies, there is a potential risk of developing secondary cancers. The FDA has updated the Black Box Warning to include the risk of secondary hematological malignancies, including T-cell malignancies, which have been reported following treatment with CD19-directed CAR T-cell immunotherapies.[11] This has prompted ongoing safety reviews by both the FDA and the EMA and underscores the need for lifelong monitoring of patients who receive this therapy.[40]

5.3. The YESCARTA and TECARTUS REMS Program

Given the potential for severe and life-threatening CRS and ICANS, axicabtagene ciloleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).[10] The purpose of the REMS is to ensure the benefits of the drug outweigh its risks.

• Mandate and Purpose: The REMS program is mandated by the FDA to inform and educate healthcare professionals about the risks and to ensure that the infrastructure is in place to manage them safely.[10]
• Requirements: The program has several key requirements:

1. Certified Facilities: Only healthcare facilities that are specially certified can dispense and administer Yescarta. These centers must have on-site, immediate access to tocilizumab and be equipped to manage severe toxicities.[1] There are over 150 such certified centers in the US.[58]
2. Trained Providers: Healthcare providers who prescribe, dispense, or administer the therapy must complete specific training on the management of CRS and ICANS.[10]
3. Patient Monitoring: Patients must be monitored daily for the first 7 days following infusion for signs and symptoms of CRS and neurologic events. They are also counseled to remain in close proximity to the certified treatment center for at least 4 weeks post-infusion to allow for prompt medical intervention if toxicities arise.[23]

Toxicity	Grade	Key Clinical Features	Recommended Management
CRS	1	Fever ≥38°C. No hypotension or hypoxia.	Symptomatic treatment (e.g., antipyretics).
	2	Fever with hypotension responsive to fluids or low-dose vasopressor OR hypoxia requiring low-flow nasal cannula.	Administer tocilizumab. Consider corticosteroids if no improvement.
	3	Fever with hypotension requiring high-dose or multiple vasopressors OR hypoxia requiring high-flow oxygen or non-invasive positive pressure ventilation.	Administer tocilizumab. Administer corticosteroids (e.g., dexamethasone).
	4	Fever with life-threatening symptoms; requires mechanical ventilation or significant organ toxicity.	Administer tocilizumab. Administer high-dose corticosteroids (e.g., methylprednisolone).
ICANS	1	ICE Score 7-9. Mild disturbance in attention, language, or orientation.	Supportive care. Monitor closely.
	2	ICE Score 3-6. Aphasia, lethargy, or significant confusion.	Administer corticosteroids (e.g., dexamethasone).
	3	ICE Score 0-2. Depressed level of consciousness (awakens to voice), seizures (non-convulsive), or focal motor weakness.	Administer higher dose corticosteroids. Escalate level of care.
	4	ICE Score 0. Stupor/coma (unrousable), life-threatening seizures, or motor findings like decerebrate posturing.	Administer high-dose corticosteroids (e.g., methylprednisolone). Manage as a neurologic emergency.
Simplified from ASTCT consensus guidelines.33 ICE: Immune Effector Cell-Associated Encephalopathy score.

VI. Comparative Efficacy and Cost-Effectiveness

The approval of axicabtagene ciloleucel was followed by the approval of other CD19-directed CAR T-cell therapies, creating a competitive landscape where clinicians must weigh the distinct profiles of each product. Furthermore, the high cost of these therapies necessitates a careful evaluation of their economic value.

6.1. Positioning in the CAR-T Armamentarium

The main competitors for axicabtagene ciloleucel (axi-cel) in the treatment of LBCL are tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel). While no head-to-head randomized trials have been conducted, a combination of cross-trial comparisons, real-world evidence, and matching-adjusted indirect comparisons provides a picture of their relative strengths and weaknesses.

Axi-cel vs. Tisagenlecleucel (tisa-cel)

• Construct and Manufacturing: The most fundamental difference lies in the CAR construct. Axi-cel uses a CD28 co-stimulatory domain, whereas tisa-cel uses a 4-1BB domain.[26] This design difference is thought to be the primary driver of their distinct clinical behaviors. Analysis of the manufactured products shows that axi-cel is comprised of more central memory T-cells, while tisa-cel contains more proliferative T-cells.[26] In terms of logistics, real-world data shows axi-cel has a shorter median manufacturing TAT compared to tisa-cel (e.g., 41 vs 52 days in one study).[59]
• Efficacy and Toxicity: The choice of co-stimulatory domain appears to create a trade-off between efficacy and toxicity. Multiple real-world studies and registries have suggested that axi-cel is associated with greater efficacy, including higher response rates and better progression-free survival (PFS), compared to tisa-cel.[26] However, this comes at the cost of significantly higher rates and severity of both CRS and ICANS.[26] While some studies have shown similar efficacy outcomes, the general consensus is that axi-cel is a more potent but also more toxic therapy than tisa-cel.[59]

Axi-cel vs. Lisocabtagene maraleucel (liso-cel)

• Efficacy and Toxicity: Liso-cel, which also uses a 4-1BB co-stimulatory domain, has a safety profile that appears more favorable than axi-cel's. Retrospective and indirect comparisons consistently show that axi-cel is associated with significantly higher rates of any-grade and severe CRS and ICANS compared to liso-cel.[35] The efficacy comparison is more complex. Some analyses show similar complete response rates and PFS between the two products.[35] However, one institutional analysis, after adjusting for patient risk factors, found an inferior PFS for liso-cel compared to axi-cel. The authors noted that liso-cel's significantly longer manufacturing time (median 41 vs 30 days) may have created a selection bias, where only patients with less aggressive disease or better performance status could wait for the liso-cel product, potentially confounding the direct comparison.[35]

The comparative data reveals that the choice of CAR-T therapy is not straightforward but rather a complex clinical negotiation. There is no single "best" product for all patients. Instead, a clear trade-off exists. Axi-cel can be viewed as the "high-octane" option, offering the potential for the most rapid and potent efficacy, which may be crucial for patients with highly aggressive or bulky disease. However, this comes with the highest risk of severe acute toxicities, requiring robust institutional support and potentially excluding more frail or older patients. Liso-cel and tisa-cel offer a more favorable safety profile, making them attractive options for patients in whom toxicity is a primary concern. Critically, the non-clinical, logistical factor of manufacturing TAT emerges as a decisive element in real-world practice. A clinician's choice is therefore a multi-variable equation, balancing the patient's disease biology, physiological fitness, and the practical reality of how quickly the personalized therapy can be manufactured and delivered before the patient's condition deteriorates.

6.2. Economic Considerations

The advent of CAR T-cell therapy has introduced unprecedented costs into the healthcare system, raising critical questions about affordability and value.

• Acquisition Cost: Axicabtagene ciloleucel has a very high list price. At its launch in 2017, the price was set at $373,000 for the one-time infusion.[15] More recent sources cite a list price of $424,000, with the total cost per treatment regimen, including ancillary services, estimated to be around $537,592.[14] These costs do not include hospitalization, management of toxicities, or subsequent care, which can add substantially to the overall expense.
• Cost-Effectiveness: Despite the formidable upfront cost, multiple health economic analyses have concluded that axicabtagene ciloleucel is a cost-effective intervention from a payer's perspective, particularly when compared to other CAR-T therapies or the historical costs of managing refractory disease.[15] In Japan, one analysis found axi-cel to be the dominant strategy, providing more life years and quality-adjusted life years (QALYs) at a lower total cost compared to tisa-cel and liso-cel.[16] The value is driven by its potential to induce durable, long-term remissions or cures. A single, curative infusion, even at a high price, can be more cost-effective in the long run than years of subsequent, less effective therapies, palliative care, and end-of-life costs that would otherwise be incurred by patients with refractory lymphoma.[15] However, the high short-term budget impact remains a significant challenge for healthcare systems.[15]

Feature	Axicabtagene ciloleucel (Yescarta)	Tisagenlecleucel (Kymriah)	Lisocabtagene maraleucel (Breyanzi)
Co-stimulatory Domain	CD28 21	4-1BB 26	4-1BB 35
Typical Manufacturing TAT	Shorter (e.g., ~14-17 days) 13	Longer (e.g., ~52 days) 59	Longer (e.g., ~35-41 days) 35
Efficacy Profile (General)	High efficacy, rapid responses 26	Effective, potentially less rapid onset	High efficacy, comparable to axi-cel in some studies 35
Toxicity Profile (CRS/ICANS)	Highest rates and severity 26	Lower rates and severity 26	Low rates and severity 35
Key Patient Population Consideration	Patients who can tolerate higher toxicity risk; need for rapid treatment	Patients where toxicity is a major concern	Older or less fit patients; those for whom a longer wait time is acceptable

VII. Conclusion and Future Directions

Axicabtagene ciloleucel has fundamentally and irrevocably altered the treatment landscape for relapsed and refractory B-cell lymphomas. By harnessing the power of the patient's own immune system, this first-in-class CD28-based CAR T-cell therapy has established a new benchmark for efficacy. Its ability to induce deep, durable, and potentially curative responses with a single infusion has provided unprecedented hope for a patient population with a historically dismal prognosis, for whom few, if any, effective options previously existed.[4] The journey of axicabtagene ciloleucel from a last-resort salvage therapy to a new standard of care in the second-line setting, as cemented by the ZUMA-7 trial, represents a triumph of immuno-oncology and a validation of the entire field of cellular therapy.

However, the field is not static. The initial challenges posed by the therapy's significant toxicities are being met with growing clinical experience and evolving management protocols. Real-world evidence now indicates a decreasing trend in the incidence, severity, and duration of CRS and ICANS over time, as clinicians become more adept at prophylactic and pre-emptive management strategies.[19] This continuous learning is steadily improving the therapeutic index of axicabtagene ciloleucel, making it a safer and more manageable option.

The future of axicabtagene ciloleucel and CAR T-cell therapy is focused on several key areas of innovation:

• Manufacturing and Logistical Optimization: The "vein-to-vein" time remains a critical variable. Kite/Gilead is engaged in continuous manufacturing process improvements, which have already resulted in highly reliable first-pass success rates and a predictable, shorter TAT.[18] Further shortening this timeline and potentially decentralizing manufacturing could make the therapy accessible to more patients and allow for its use in those with more fulminant disease.
• Toxicity Mitigation and Next-Generation Constructs: A primary goal of ongoing research is to uncouple the profound efficacy of CAR T-cell therapy from its severe toxicities. This includes refining management protocols, such as the use of prophylactic corticosteroids [45], and exploring novel combination therapies. The ZUMA-11 trial, for instance, is investigating the addition of the 4-1BB agonist antibody utomilumab to axi-cel, with the hypothesis that providing a dual co-stimulatory signal (CD28 from the CAR and 4-1BB from the antibody) could enhance CAR T-cell expansion and persistence while potentially modulating the toxicity profile.[27]
• Expansion to Earlier Lines of Therapy and New Indications: The success of ZUMA-7 has opened the door to testing CAR-T therapy even earlier in the treatment course. A pivotal Phase 3 trial (NCT05605899) is currently underway comparing axicabtagene ciloleucel directly against the standard R-CHOP chemoimmunotherapy as a first-line treatment for patients with high-risk LBCL.[17] Success in this trial would represent the ultimate paradigm shift.
• Novel Combination Strategies: Research is also exploring the synergy between axicabtagene ciloleucel and other novel agents. A Phase 2 study (NCT06213311) is evaluating its combination with the bispecific antibody glofitamab in the second-line setting, aiming to further deepen responses and overcome resistance mechanisms.[63]

In conclusion, axicabtagene ciloleucel is more than just a drug; it is the vanguard of a living, evolving field of medicine. While challenges related to toxicity, cost, and access remain, the pace of innovation is rapid. The ongoing efforts to refine its delivery, improve its safety, and expand its application promise to further solidify its role as a transformative therapy, offering the potential for a cure to an ever-wider population of patients with hematologic malignancies.

Works cited

1. Axicabtagene ciloleucel - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
2. Axicabtagene ciloleucel: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB13915
3. What is the mechanism of Axicabtagene Ciloleucel? - Patsnap Synapse, accessed August 6, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-axicabtagene-ciloleucel
4. Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma 5-Year Results of the ZUMA-1 Trial - The ASCO Post, accessed August 6, 2025, https://ascopost.com/issues/march-25-2023/axicabtagene-ciloleucel-in-refractory-large-b-cell-lymphoma-5-year-results-of-the-zuma-1-trial/
5. 5-year outcomes of axicabtagene ciloleucel in adults with refractory LBCL: ZUMA-1 trial, accessed August 6, 2025, https://lymphomahub.com/medical-information/5-year-outcomes-of-axicabtagene-ciloleucel-in-adults-with-refractory-lbcl-zuma-1-trial
6. Overall Survival With Axicabtagene Ciloleucel in Large B-Cell Lymphoma Results From ZUMA-7 - The ASCO Post, accessed August 6, 2025, https://ascopost.com/news/july-2023/overall-survival-with-axicabtagene-ciloleucel-in-large-b-cell-lymphoma-results-from-zuma-7/
7. FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-cell Lymphoma - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10767767/
8. Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7, accessed August 6, 2025, https://jhoponline.com/issue-archive/2022-issues/april-2022-vol-12-no-2/second-line-axicabtagene-ciloleucel-therapy-improves-outcomes-in-patients-with-large-b-cell-lymphoma-zuma-7
9. Safety - YESCARTA® (axicabtagene ciloleucel), accessed August 6, 2025, https://www.yescartahcp.com/large-b-cell-lymphoma/safety
10. U.S. FDA Approves New Label Update for CAR T Cell Therapy Yescarta Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome - Gilead Sciences, accessed August 6, 2025, https://www.gilead.com/news/news-details/2022/us-fda-approves-new-label-update-for-car-t-cell-therapy-yescarta-showing-prophylactic-steroid-use-improves-management-of-cytokine-release-syndrome
11. Package Insert and Medication Guide - YESCARTA - FDA, accessed August 6, 2025, https://www.fda.gov/media/108377/download
12. Kite's Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy - Gilead Sciences, accessed August 6, 2025, https://www.gilead.com/news/news-details/2017/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-after-two-or-more
13. YESCARTA® (axicabtagene ciloleucel): Large B-Cell Lymphoma, accessed August 6, 2025, https://www.yescartahcp.com/large-b-cell-lymphoma
14. www.drugs.com, accessed August 6, 2025, [https://www.drugs.com/medical-answers/cost-yescarta-3342568/#:~:text=Medically%20reviewed%20by%20Leigh%20Ann,updated%20on%20July%203%2C%202025.&text=The%20cost%20of%20Yescarta%20(axicabtagene,the%20costs%20for%20this%20treatment.](https://www.google.com/url?q=https://www.drugs.com/medical-answers/cost-yescarta-3342568/%23:~:text%3DMedically%2520reviewed%2520by%2520Leigh%2520Ann,updated%2520on%2520July%25203%252C%25202025.%26text%3DThe%2520cost%2520of%2520Yescarta%2520(axicabtagene,the%2520costs%2520for%2520this%2520treatment.&sa=D&source=editors&ust=1754466736128890&usg=AOvVaw0Lzad6wthK-sAdp8q9T9oQ)
15. Institute for Clinical and Economic Review Report Finds Costs of Approved CAR-T Therapies Align with Clinical Benefit - ICER, accessed August 6, 2025, https://icer.org/news-insights/press-releases/car-t-evidence-report/
16. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan - Taylor & Francis Online, accessed August 6, 2025, https://www.tandfonline.com/doi/abs/10.2217/fon-2023-1114
17. Axicabtagene ciloleucel Recruiting Phase 3 Trials for High-risk Large B-cell Lymphoma (LBCL) Treatment - DrugBank, accessed August 6, 2025, https://go.drugbank.com/drugs/DB13915/clinical_trials?conditions=DBCOND0152662&phase=3&purpose=treatment&status=recruiting
18. Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients with Relapsed/Refractory Large B-Cell Lymphoma | Blood | American Society of Hematology, accessed August 6, 2025, https://ashpublications.org/blood/article/144/Supplement%201/3477/529459/Improvements-in-Axicabtagene-Ciloleucel
19. Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH - Gilead Sciences, accessed August 6, 2025, https://www.gilead.com/news/news-details/2024/kite-presents-new-data-underscoring-curative-potential-of-yescarta-in-relapsedrefractory-large-b-cell-lymphoma-at-ash
20. Technology - Axicabtagene Ciloleucel for Large B-Cell Lymphoma - NCBI, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK550088/
21. Yescarta, INN-axicabtagene ciloleucel, accessed August 6, 2025, https://ec.europa.eu/health/documents/community-register/2022/20220621156017/anx_156017_en.pdf
22. Axicabtagene Ciloleucel - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Axicabtagene-Ciloleucel
23. Yescarta, INN-axicabtagene ciloleucel - EMA, accessed August 6, 2025, https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf
24. pmc.ncbi.nlm.nih.gov, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7517758/#:~:text=PHARMACOLOGY%20AND%20MECHANISM%20OF%20ACTION&text=After%20axi%2Dcel%20binds%20to,destruction%20of%20CD19%2Dpositive%20cells.
25. Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7517758/
26. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing | Journal for ImmunoTherapy of Cancer, accessed August 6, 2025, https://jitc.bmj.com/content/13/7/e011807
27. Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11 - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10570684/
28. Manufacturing & Process | YESCARTA® (axicabtagene ciloleucel), accessed August 6, 2025, https://www.yescartahcp.com/large-b-cell-lymphoma/manufacturing-and-process
29. Global Manufacturing of CAR T Cell Therapy - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5363291/
30. Enhancing Speed in CAR-T Cell Manufacturing with Cell Therapy Solutions - Behind the Bench - Thermo Fisher Scientific, accessed August 6, 2025, https://www.thermofisher.com/blog/behindthebench/enhancing-speed-in-car-t-cell-manufacturing-with-cell-therapy-solutions/
31. Accelerating CAR T cell manufacturing with an automated next-day process | bioRxiv, accessed August 6, 2025, https://www.biorxiv.org/content/10.1101/2024.06.04.596536v1.full
32. CAR T Cell Manufacturing - MaxCyte, accessed August 6, 2025, https://maxcyte.com/applications/cell-therapy/car-t/
33. Yescarta (axicabtagene ciloleucel) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 6, 2025, https://reference.medscape.com/drug/yescarta-axicabtagene-ciloleucel-1000187
34. FDA approves axicabtagene ciloleucel for large B-cell lymphoma, accessed August 6, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma
35. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma | Blood Advances | American Society of Hematology, accessed August 6, 2025, https://ashpublications.org/bloodadvances/article/9/3/455/525995/A-real-world-comparison-of-commercial-use
36. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/39546746/
37. Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting | Blood, accessed August 6, 2025, https://ashpublications.org/blood/article/142/Supplement%201/2131/503343/Lisocabtagene-Maraleucel-Versus-Axicabtagene
38. Axicabtagene Ciloleucel Submitted for EU Approval in Non-Hodgkin Lymphoma, accessed August 6, 2025, https://www.targetedonc.com/view/axicabtagene-ciloleucel-submitted-for-eu-approval-in-nonhodgkin-lymphoma
39. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5987753/
40. Axicabtagene Ciloleucel - PEPID Connect, accessed August 6, 2025, https://www.pepidconnect.com/Default.aspx?new=2&accessCode=Yescarta
41. Axicabtagene Ciloleucel (Yescarta) - Medical Clinical Policy Bulletins - Aetna, accessed August 6, 2025, https://www.aetna.com/cpb/medical/data/900_999/0924.html
42. Axicabtagene ciloleucel - Kite Pharma - AdisInsight - Springer, accessed August 6, 2025, https://adisinsight.springer.com/drugs/800039436
43. www.techtransfer.nih.gov, accessed August 6, 2025, https://www.techtransfer.nih.gov/sites/default/files/documents/pdfs/Impact%20Study/Yescarta%20Case%20Study.pdf
44. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7543293/
45. Yescarta (axicabtagene ciloleucel) FDA Approval History - Drugs.com, accessed August 6, 2025, https://www.drugs.com/history/yescarta.html
46. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma, accessed August 6, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma
47. Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy - Gilead Sciences, accessed August 6, 2025, https://www.gilead.com/news/news-details/2018/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy
48. EU/3/15/1579 - orphan designation for treatment of follicular lymphoma | European Medicines Agency (EMA), accessed August 6, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1579
49. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/29226797/
50. Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - ClinicalTrials.gov, accessed August 6, 2025, https://clinicaltrials.gov/study/NCT02348216
51. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. - ASCO, accessed August 6, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT211541
52. Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/​Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) - ClinicalTrials.gov, accessed August 6, 2025, https://www.clinicaltrials.gov/study/NCT03391466
53. Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7 - Journal of Hematology Oncology Pharmacy, accessed August 6, 2025, https://www.jhoponline.com/articles/second-line-axicabtagene-ciloleucel-therapy-improves-outcomes-in-patients-with-large-b-cell-lymphoma-zuma-7
54. Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma. - ASCO Publications, accessed August 6, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA107
55. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma - American Society of Hematology, accessed August 6, 2025, https://ashpublications.org/blood/article/140/21/2248/485937/Patient-reported-outcomes-in-ZUMA-7-a-phase-3
56. Axicabtagene ciloleucel | Leukemia and Lymphoma Society, accessed August 6, 2025, https://www.lls.org/drug/axicabtagene-ciloleucel
57. EMA Begins Safety Review of CAR T-Cell Therapies - AABB.org, accessed August 6, 2025, https://www.aabb.org/news-resources/news/article/2024/01/19/ema-begins-safety-review-of-car-t-cell-therapies
58. YESCARTA® (axicabtagene ciloleucel) Patient & Caregiver Site | CAR T-Cell Therapy for Certain Types of Non-Hodgkin Lymphoma in Adults, accessed August 6, 2025, https://www.yescarta.com/
59. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma | Haematologica, accessed August 6, 2025, https://haematologica.org/article/view/haematol.2022.280805
60. Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/40079097/
61. What is the cost of Yescarta? - Drugs.com, accessed August 6, 2025, https://www.drugs.com/medical-answers/cost-yescarta-3342568/
62. How Is Yescarta Used to Treat Lymphoma? - GoodRx, accessed August 6, 2025, https://www.goodrx.com/yescarta/how-does-yescarta-treat-lymphoma
63. Axicabtagene ciloleucel Recruiting Phase 2 Trials for B-Cell Lymphoma Treatment, accessed August 6, 2025, https://go.drugbank.com/drugs/DB13915/clinical_trials?conditions=DBCOND0028340&phase=2&purpose=treatment&status=recruiting